A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Completed · Phase 3 · NCT01650701
Conditions: Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $614,370
- U.S. investigators named
- 16
- Sites paid
- 15
- Planned or actual enrollment
- 1,030
About the trial
- Sponsor
- The Lymphoma Academic Research Organisation (with Celgene Corporation)
- Tested
- Rituximab (drug), Lenalidomide (drug), Rituximab - CHOP (drug), Rituximab - CVP (drug), Rituximab - Bendamustine (drug)
- Dates
- Started 2012-02; completion 2024-04-30
- Results posted
- Not yet
The purpose of this study is to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length of your response (complete or partial response) compared to the standard of care rituximab chemotherapy treatment.
From ClinicalTrials.gov, last updated 2025-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $614,370 in research payments for this study in 2025 (16 payments).
Products named: Revlimid
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mikhail I. Shtivelband, MD Hematology & Oncology · Chandler, AZ
- Herbert A. Eradat, M.D., M.S. Internal Medicine · Los Angeles, CA
- Giribala R. Patel, M.D. Medical Oncology · Fullerton, CA
- Robert J. Hoyer, M.D. Hematology & Oncology · Colorado Springs, CO
- Hatem Hassanein, M.D. Medical Oncology · Orlando, FL
- Denise A. Levitan, MD Medical Oncology · Chicago, IL
- Jeffrey A. Barnes, M.D., PH.D Hematology & Oncology · Boston, MA
- David E. Fisher, MD PHD Medical Oncology · Boston, MA
- Nancy L. Bartlett, MD Medical Oncology · Saint Louis, MO
- Andre H. Goy, MD Medical Oncology · Hackensack, NJ
- Maria L. Palomba, MD Hematology & Oncology · New York, NY
- Ian W. Flinn, M.D. Hematology & Oncology · Nashville, TN
- Moshe Y. Levy, MD Medical Oncology · Dallas, TX
- Donald P. Quick, MD Hematology & Oncology · Lubbock, TX
- Jason Westin, M.D. Medical Oncology · Houston, TX
- Yuvraj Choudhary, M.D. Hematology & Oncology · North Chesterfield, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ronald Reagan UCLA Medical Center, CA $169,410
- Ut MD Anderson Cancer Center $113,711
- Tennessee Oncology, PLLC $65,817
- Washington University $49,026
- Hackensack University Medical Center, NJ $48,531
- Sloan Kettering Institute for Cancer Research $46,544
- Baylor Research Institute $35,253
- Dana Farber Cancer Institute, Inc $32,187
- Virginia Cancer Institute $16,440
- Methodist Childrens Hospital $10,717
- Orlando Health, FL $10,339
- Advocate Christ Hospital & Medical Center, IL $7,138
- Memorial Health System $3,627
- Saint Joseph Health System $3,279
- Ironwood Cancer & Researc $2,350
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.